Psoriasis Therapeutics Pipeline to Witness Many Collaborations in the Coming Years

Published Date:   October 2017

Psoriasis currently exhibits a strong pipeline with 150 drug candidates, according to P&S Intelligence

Psoriasis therapeutics pipeline in 2017

The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of the skin, causing patches of psoriasis to appear. There are five types of psoriasis namely, plaque psoriasis or psoriasis vulgaris, guttate psoriasis, inverse psoriasis or flexural psoriasis or intertriginous psoriasis, pustular psoriasis, and erythrodermic or exfoliative psoriasis.

Access Report Summary with Detailed TOC on “Psoriasis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at:

Insights on pipeline segments

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.

PAD technology platform for psoriasis drug development

MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.

Various collaborations for psoriasis drug development

Boehringer Ingelheim GmbH and AbbVie, Inc. entered in a worldwide agreement to develop and commercialize BI 655066, for the treatment of psoriasis.
Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

Psoriasis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Send An Enquiry

Secure Lock  By clicking the SUBMIT REQUEST below, you also agree to abide by the Terms and Conditions of the company

Secure Lock  We respect your privacy. Your information will not be shared.